Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviews

被引:7
|
作者
Studzinski, Krzysztof [1 ]
Tomasik, Tomasz [1 ]
Krzyszton, Janusz [1 ]
Jozwiak, Jacek [2 ]
Windak, Adam [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Family Med, Chair Internal Med & Gerontol, Krakow, Poland
[2] Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, Poland
来源
BMJ OPEN | 2017年 / 7卷 / 03期
关键词
CORONARY-HEART-DISEASE; VALIDATION; STRATEGIES; DERIVATION; SCORES; IMPACT; CHART;
D O I
10.1136/bmjopen-2016-014206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Major clinical practice guidelines recommend assessing risk of cardiovascular disease (CVD) using absolute/global/total CVD risk scores. However, the effectiveness of using them in clinical practice, despite publication of numerous randomised controlled trials (RCTs), is still poorly understood. To summarise and analyse current knowledge in this field, we will carry out an overview of existing systematic reviews (SRs). The objective of this overview will be to assess the effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of CVD compared with standard care. Methods and analysis: We will include SRs and meta-analyses which take into account RCTs and quasi-RCTs investigating the effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of CVD. SRs will be retrieved from 4 bibliographical databases and reference lists of identified reviews. Additionally, the PROSPERO database will be searched for unpublished, ongoing or recently completed SRs. 2 reviewers will assess the SRs independently for eligibility and bias. The data will be extracted to a special form. Any disagreement will be resolved by discussion. In case of lack of consensus, a third author will arbitrate. The overview of SRs will be reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement. Ethics and dissemination: Ethics approval is not required for overview of SRs. We will summarise evidence concerning whether use of the absolute/ global/total CVD risk scoring tools in primary prevention of CVD is effective and supported with scientific data or not. If we face unsatisfactory confirmation, we will highlight a need for further research and advice on how to plan such a study. We will submit the results of our study for peer-review publication in a journal indexed in the international bibliographic database of biomedical information.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews
    Studzinski, Krzysztof
    Tomasik, Tomasz
    Krzyszton, Janusz
    Jozwiak, Jacek
    Windak, Adam
    [J]. BMC CARDIOVASCULAR DISORDERS, 2019, 19 (1)
  • [2] Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews
    Krzysztof Studziński
    Tomasz Tomasik
    Janusz Krzysztoń
    Jacek Jóźwiak
    Adam Windak
    [J]. BMC Cardiovascular Disorders, 19
  • [3] Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews
    Collins, Dylan R. J.
    Tompson, Alice C.
    Onakpoya, Igho J.
    Roberts, Nia
    Ward, Alison M.
    Heneghan, Carl J.
    [J]. BMJ OPEN, 2017, 7 (03):
  • [4] Risk scoring for the primary prevention of cardiovascular disease
    Karmali, Kunal N.
    Persell, Stephen D.
    Perel, Pablo
    Lloyd-Jones, Donald M.
    Berendsen, Mark A.
    Huffman, Mark D.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (03):
  • [5] Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
    Byrne, Paula
    Cullinan, John
    Smith, Amelia
    Smith, Susan M.
    [J]. BMJ OPEN, 2019, 9 (04):
  • [6] Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease An Overview of Systematic Reviews
    Karmali, Kunal N.
    Lloyd-Jones, Donald M.
    Berendsen, Mark A.
    Goff, David C., Jr.
    Sanghavi, Darshak M.
    Brown, Nina C.
    Korenovska, Liliya
    Huffman, Mark D.
    [J]. JAMA CARDIOLOGY, 2016, 1 (03) : 341 - 349
  • [7] Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews
    Karmali, K. N.
    Loyd-Jones, D. M.
    Berendsen, M. A.
    [J]. JAMA CARDIOLOGY, 2017, 2 (04) : 461 - 461
  • [8] Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease
    Dyakova, Mariana
    Shantikumar, Saran
    Colquitt, Jill L.
    Drew, Christian
    Sime, Morag
    MacIver, Joanna
    Wright, Nicola
    Clarke, Aileen
    Rees, Karen
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (01):
  • [9] Barriers to cardiovascular disease risk scoring and primary prevention in Europe
    Hobbs, F. D. R.
    Jukema, J. W.
    Da Silva, P. M.
    McCormack, T.
    Catapano, A. L.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (10) : 727 - 739
  • [10] Risk factors for dementia in the context of cardiovascular disease: A protocol of an overview of reviews
    Brain, Jacob
    Tully, Phillip J.
    Turnbull, Deborah
    Tang, Eugene
    Greene, Leanne
    Beach, Sarah
    Siervo, Mario
    Stephan, Blossom C. M.
    [J]. PLOS ONE, 2022, 17 (07):